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ABSTRACT
Background: The causes of inflammatory bowel disease (IBD) have not yet been clearly elucidated, but it is known that genetic susceptibility, 
altered gut microbiota and environmental factors are all involved, and that a combination of these factors causes an inappropriate immune 
response, resulting in impaired intestinal barrier function. With regard to the treatment of IBD, the use of conventional immunosuppressive 
drugs has been complemented by more specific therapeutic agents, including biological drugs. Systemic immune suppression is a risk factor 
for cytomegalovirus (CMV) infection, which is associated with considerable morbidity and mortality in immunocompromised hosts.
Case Report: A 33-year-old male patient was admitted to our medical unit complaining of a 10-day history of fever, fatigue and headache. He 
had been suffering from ulcerative colitis and primary sclerosing cholangitis for five years and was currently being treated with azathioprine 
and vedolizumab. In the past he had already taken infliximab, adalimumab and golimumab without any clinical response. After the exclusion 
of systemic infectious diseases, his serology was consistent with a primary CMV infection. This was successfully treated with intravenous 
ganciclovir therapy.
Conclusion: Vedolizumab is an anti-integrin biological agent approved for IBD treatment. Its gut-selective mechanism of action would appear 
to increase its safety profile, however data on this are still limited. Moreover, it should always be remembered that IBD patients have an 
increased risk of CMV infection, both primary and reactivation, because of their concurrent immunosuppression.
LEARNING POINTS
• It is important to consider CMV infection (primary and reactivation) in patients affected by IBD.
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INTRODUCTION
During the past two decades, the treatment of IBD has been revolutionised with conventional treatments complemented by the advent 
of biological drugs that target specific molecules of inflammation-related pathways, to induce intestinal mucosal healing and change the 
progression of the disease.
Anti-tumour necrosis factor (TNF) agents were the first biologics used to treat IBD, however both the first- and second-generation TNF-
antagonists failed to show an effect across all IBD patients: 10%-30% were primary non-responders, while loss of response was seen in 23%-
46% [1]. More recently, newer biological drugs, called anti-integrins, have been developed and used successfully. These prevent lymphocyte 
recruitment to the site of inflammation by blocking the interaction between integrins (cell surface proteins expressed by circulating immune 
cells) and cell adhesion molecules (CAMs), such as MAdCAM-1, which is expressed on the endothelium of intestinal mucosal blood vessels.
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Vedolizumab can be used in moderate-severe IBD patients who did not respond or were intolerant to first- and second-line therapies. 
Vedolizumab prevents α4β7-integrin on lymphocyte membrane from binding to its ligand MAdCAM-1: this gut-selective mechanism 
prevents lymphocyte recruitment to the inflamed IBD mucosa [2].
CASE REPORT
A 33-year-old male patient was admitted to our medical unit because of a 10-day history of fever (up to 39°C), not responsive to paracetamol. 
He also complained of fatigue and right frontal headache, associated with nausea and photophobia. He reported 5 bowel movements per 
day on average, with mucus but no previous bleeding. For the past five years had been suffering from ulcerative colitis (UC) and primary 
sclerosing cholangitis. His whole colon was involved and he had already taken infliximab, adalimumab and golimumab, without any clinical 
response. He had never been exposed to steroid therapy. At the time of admission, he had been under treatment with azathioprine (50 
mg bid) and vedolizumab (300 mg every 8 weeks) for four months with a good clinical response and no signs of flares on laboratory and 
endoscopic evaluations. Both focal neurological and meningeal signs were negative. Chest X-ray, head CT, brain MRI and eye examinations 
were all unremarkable. On the neurologist’s advice, lumbar puncture was not performed as his headache was interpreted as a symptom of 
systemic infection. He was started on empirical antibiotic treatment with intravenous (IV) ceftriaxone and oral levofloxacin. Blood tests 
showed mild anaemia and thrombocytopenia without lymphocytosis.
Urine and blood cultures were negative, and echocardiogram did not show any evidence of endocarditis. Abdominal ultrasound showed 
splenomegaly and PET/CT imaging was compatible with an IBD flare. Faecal calprotectin was markedly increased (> 2000 mcg/g), while 
stool cultures were negative for intestinal infections, including Clostridium difficile. Furthermore, diagnostic tests for malaria parasites, 
Brucella, toxoplasma, Borrelia, Rickettsiae, leishmaniasis, beta-D-glucan and HIV were negative, as were other tests: quantiferon, monotest 
and antistreptolysin O titer (ASLOT).
A few days later his serology was consistent with a primary CMV infection: IgG were absent (<5 U/ml), while IgM were higher than normal 
(117 U/ml) and CMV DNA levels displayed an incremental trend (from 1739 to 2819 UI/m). Since the patient was also immunosuppressed, 
IV injections of ganciclovir (5 mg/kg) twice a day for two weeks were administered and azathioprine was stopped. His fever disappeared and 
his general conditions rapidly improved, so the patient was discharged. He continued with oral ganciclovir therapy (5 mg/kg bid) for 14 days. 
He also took mesalazine (800 mg bid) until the next colonoscopy.
DISCUSSION
Cytomegalovirus (CMV) is a ubiquitous virus and its seroprevalence in the general population ranges from 40 to 100%. Primary CMV 
infection in the immunocompetent host is often asymptomatic, while in immunocompromised individuals it can be associated with 
considerable morbidity and mortality.
This opportunistic pathogen is more commonly detected in medically refractory UC than in Crohn’s disease because of their different 
immunological backgrounds[3]. The prevalence of CMV reactivation in moderate-to-severe colitis has been reported as between 21% 
and 34%, and the prevalence of CMV in glucocorticoid refractory colitis is greater than 30%[4]. A recent study revealed that the CMV 
seroprevalence rate (primary infections) in European IBD patients is probably lower than previously thought[5]. IBD patients can be 
considered at increased risk of CMV infection, both primary and reactivation, given their immune dysregulation, reduced barrier function, 
possible malnutrition and possible immunosuppressive therapy[4]. Clinical practice guidelines issued by the Italian Group for the study of 
IBDs state that thiopurine-treated IBD patients have a 3-fold increased risk of opportunistic infections such as CMV, while IBD patients 
receiving thiopurine and steroids have a 5-fold increased risk[6]. Furthermore, a recent meta-analysis found that patients treated with 
biologics had a moderately increased risk of any infection (OR 1,19; 95% C.I. 1,10-1,29) and a significantly increased risk of opportunistic 
infections (OR 1,90; 95% C.I. 1,21-3,01)[7]. Other studies analyzed vedolizumab effectiveness and safety; in one of them, active smoking 
and concomitant use of immunosuppressive agents and corticosteroids were independently associated with infections[8]. Currently, in IBD 
patients, ganciclovir administration is indicated for primary CMV infection associated with exacerbation of colitis, and also when CMV is 
detected in colonic mucosa or in severe steroid-resistant colitis patients. For example, a recent case report showed that vedolizumab seems 
to be safe in patients with active UC and colonic CMV reactivation as long as concurrent antiviral treatment is started[9].
CONCLUSION
When we encounter fever in IBD patients, it is important to consider the possibility of CMV infection, both primary and reactivation.
Very little is known about how to manage CMV infections in patients who are being treated with anti-integrin drugs and we need more data 
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to understand how biological drugs affect the patient immune system.
Vedolizumab therapy seems to be associated with a low side-effects profile, but further real-life studies need to be conducted to improve 
our knowledge about its safety, especially when it is taken at the same time as corticosteroids.
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